64 results
8-K
EX-99.2
IMVT
Immunovant Inc
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
attractive subcutaneous injection Demonstrate minimal to no impact on LDL Demonstrate minimal to no impact on albumin 4 Goals for the Phase 1 Program
8-K
EX-99.2
IMVT
Immunovant Inc
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
, commercially attractive subcutaneous injection Demonstrate minimal to no impact on LDL Demonstrate minimal to no impact on albumin 5 Goals for the Phase 1
8-K
EX-99.2
oeagxauj
8 Jun 22
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
go4cavgvz1mmm
30 Mar 22
Regulation FD Disclosure
7:44am
8-K
EX-10.1
h8cl39
15 Sep 21
Immunovant Appoints Renee Barnett as Chief Financial Officer
7:23am